TSHR; | |
CTDSP1; TDP1; MIF; HSD17B1; AKR1B1; ALOX15; NOX4; HSD17B2; | |
GAA; | |
TRPA1; | |
DAPK1; FLT3; | |
CA2; CA1; CA12; CA9; CA5A; CA14; CA3; CA7; CA4; CA6; | |
PPARA; PPARD; | |
AR; | |
ESRRA; | |
ALOX5; TYR; XDH; | |
TLR2; | |
AHR; HIF1A; TP53; | |
ABCG2; ABCC1; | |
LMNA; FABP3; FABP5; FABP2; FABP4; MAPT; |
Protein Class | Gene ID | Protein Name | Uniprot ID | Target ChEMBL ID |
---|---|---|---|---|
ATP-binding cassette | ABCG2 | ATP-binding cassette sub-family G member 2 | Q9UNQ0 | CHEMBL5393 |
ATP-binding cassette | ABCC1 | Multidrug resistance-associated protein 1 | P33527 | CHEMBL3004 |
Cytochrome P450 family 1 | CYP1A2 | Cytochrome P450 1A2 | P05177 | CHEMBL3356 |
Cytochrome P450 family 1 | CYP1B1 | Cytochrome P450 1B1 | Q16678 | CHEMBL4878 |
Cytochrome P450 family 1 | CYP1A1 | Cytochrome P450 1A1 | P04798 | CHEMBL2231 |
Cytochrome P450 family 2 | CYP2C19 | Cytochrome P450 2C19 | P33261 | CHEMBL3622 |
Cytochrome P450 family 2 | CYP2C9 | Cytochrome P450 2C9 | P11712 | CHEMBL3397 |
Cytochrome P450 family 2 | CYP2A13 | Cytochrome P450 2A13 | Q16696 | CHEMBL3542436 |
Cytochrome P450 family 2 | CYP2A6 | Cytochrome P450 2A6 | P11509 | CHEMBL5282 |
Enzyme_unclassified | CTDSP1 | Carboxy-terminal domain RNA polymerase II polypeptide A small phosphatase 1 | Q9GZU7 | CHEMBL1795098 |
Enzyme_unclassified | TDP1 | Tyrosyl-DNA phosphodiesterase 1 | Q9NUW8 | CHEMBL1075138 |
Enzyme_unclassified | MIF | Macrophage migration inhibitory factor | P14174 | CHEMBL2085 |
Enzyme_unclassified | HSD17B1 | Estradiol 17-beta-dehydrogenase 1 | P14061 | CHEMBL3181 |
Enzyme_unclassified | AKR1B1 | Aldose reductase | P15121 | CHEMBL1900 |
Enzyme_unclassified | ALOX15 | Arachidonate 15-lipoxygenase | P16050 | CHEMBL2903 |
Enzyme_unclassified | NOX4 | NADPH oxidase 4 | Q9NPH5 | CHEMBL1250375 |
Enzyme_unclassified | HSD17B2 | Estradiol 17-beta-dehydrogenase 2 | P37059 | CHEMBL2789 |
Hydrolase | GAA | Lysosomal alpha-glucosidase | P10253 | CHEMBL2608 |
Lyase | CA2 | Carbonic anhydrase II | P00918 | CHEMBL205 |
Lyase | CA1 | Carbonic anhydrase I | P00915 | CHEMBL261 |
Lyase | CA12 | Carbonic anhydrase XII | O43570 | CHEMBL3242 |
Lyase | CA9 | Carbonic anhydrase IX | Q16790 | CHEMBL3594 |
Lyase | CA5A | Carbonic anhydrase VA | P35218 | CHEMBL4789 |
Lyase | CA14 | Carbonic anhydrase XIV | Q9ULX7 | CHEMBL3510 |
Lyase | CA3 | Carbonic anhydrase III | P07451 | CHEMBL2885 |
Lyase | CA7 | Carbonic anhydrase VII | P43166 | CHEMBL2326 |
Lyase | CA4 | Carbonic anhydrase IV | P22748 | CHEMBL3729 |
Lyase | CA6 | Carbonic anhydrase VI | P23280 | CHEMBL3025 |
Nuclear hormone receptor subfamily 1 group C | PPARA | Peroxisome proliferator-activated receptor alpha | Q07869 | CHEMBL239 |
Nuclear hormone receptor subfamily 1 group C | PPARD | Peroxisome proliferator-activated receptor delta | Q03181 | CHEMBL3979 |
Nuclear hormone receptor subfamily 3 group B | ESRRA | Estrogen-related receptor alpha | P11474 | CHEMBL3429 |
Nuclear hormone receptor subfamily 3 group C | AR | Androgen Receptor | P10275 | CHEMBL1871 |
Oxidoreductase | XDH | Xanthine dehydrogenase | P47989 | CHEMBL1929 |
Oxidoreductase | ALOX5 | Arachidonate 5-lipoxygenase | P09917 | CHEMBL215 |
Oxidoreductase | TYR | Tyrosinase | P14679 | CHEMBL1973 |
Peptide receptor (family A GPCR) | TSHR | Thyroid stimulating hormone receptor | P16473 | CHEMBL1963 |
Protein Kinase | DAPK1 | Death-associated protein kinase 1 | P53355 | CHEMBL2558 |
Protein Kinase | FLT3 | Tyrosine-protein kinase receptor FLT3 | P36888 | CHEMBL1974 |
Toll-like and Il-1 receptors | TLR2 | Toll-like receptor 2 | O60603 | CHEMBL4163 |
Transcription Factor | AHR | Aryl hydrocarbon receptor | P35869 | CHEMBL3201 |
Transcription Factor | HIF1A | Hypoxia-inducible factor 1 alpha | Q16665 | CHEMBL4261 |
Transcription Factor | TP53 | Cellular tumor antigen p53 | P04637 | CHEMBL4096 |
Transient receptor potential channel | TRPA1 | Transient receptor potential cation channel subfamily A member 1 | O75762 | CHEMBL6007 |
Unclassified | LMNA | Prelamin-A/C | P02545 | CHEMBL1293235 |
Unclassified | FABP3 | Fatty acid binding protein muscle | P05413 | CHEMBL3344 |
Unclassified | FABP5 | Fatty acid binding protein epidermal | Q01469 | CHEMBL3674 |
Unclassified | FABP2 | Fatty acid binding protein intestinal | P12104 | CHEMBL4879 |
Unclassified | FABP4 | Fatty acid binding protein adipocyte | P15090 | CHEMBL2083 |
Unclassified | MAPT | Microtubule-associated protein tau | P10636 | CHEMBL1293224 |
GO Type | GO Category | Enriched GO Terms | p-Value | Adjusted p-Value | Enriched Genes |
---|---|---|---|---|---|
MF | GO:0005488; binding | GO:0005506; iron ion binding | 7.131E-12 | 8.172E-09 | ALOX15, ALOX5, CYP1A1, CYP1A2, CYP1B1, CYP2A13, CYP2A6, CYP2C19, CYP2C9, XDH |
MF | GO:0005488; binding | GO:0019825; oxygen binding | 1.823E-11 | 1.805E-08 | CYP1A1, CYP1A2, CYP1B1, CYP2A13, CYP2C19, CYP2C9, NOX4 |
BP | GO:0008152; metabolic process | GO:0097267; omega-hydroxylase P450 pathway | 2.125E-11 | 2.012E-08 | CYP1A1, CYP1A2, CYP1B1, CYP2C19, CYP2C9 |
MF | GO:0005488; binding | GO:0020037; heme binding | 1.071E-09 | 6.135E-07 | CYP1A1, CYP1A2, CYP1B1, CYP2A13, CYP2A6, CYP2C19, CYP2C9, NOX4 |
MF | GO:0005488; binding | GO:0008270; zinc ion binding | 8.387E-09 | 4.247E-06 | AR, CA1, CA12, CA2, CA3, CA4, CA5A, CA6, CA7, CA9, ESRRA, PPARA, PPARD, TP53 |
BP | GO:0050896; response to stimulus | GO:0042738; exogenous drug catabolic process | 1.782E-08 | 8.435E-06 | CYP1A2, CYP2A6, CYP2C19, CYP2C9 |
BP | GO:0050896; response to stimulus | GO:0033993; response to lipid | 1.891E-08 | 8.762E-06 | AR, CA2, CA9, CYP1A1, CYP1A2, ESRRA, FABP3, FLT3, HSD17B2, PPARD, TLR2, TP53, TYR |
BP | GO:0050896; response to stimulus | GO:0014070; response to organic cyclic compound | 2.052E-08 | 9.308E-06 | AR, CA2, CA9, CYP1A1, CYP1A2, CYP1B1, ESRRA, FLT3, NOX4, TLR2, TP53, TRPA1, TYR |
MF | GO:0003824; catalytic activity | GO:0008395; steroid hydroxylase activity | 2.242E-08 | 9.964E-06 | CYP1A1, CYP2A13, CYP2A6, CYP2C19, CYP2C9 |
MF | GO:0003824; catalytic activity | GO:0008392; arachidonic acid epoxygenase activity | 8.488E-08 | 3.554E-05 | CYP2A13, CYP2A6, CYP2C19, CYP2C9 |
MF | GO:0140110; transcription regulator activity | GO:0004879; nuclear receptor activity | 1.493E-07 | 5.979E-05 | AHR, AR, ESRRA, PPARA, PPARD |
BP | GO:0008152; metabolic process | GO:0016098; monoterpenoid metabolic process | 3.052E-07 | 1.072E-04 | CYP1A2, CYP2C19, CYP2C9 |
MF | GO:0003824; catalytic activity | GO:0070330; aromatase activity | 3.123E-07 | 1.079E-04 | CYP1A1, CYP1A2, CYP1B1, CYP2A13 |
BP | GO:0008152; metabolic process | GO:0019433; triglyceride catabolic process | 4.445E-07 | 1.423E-04 | FABP2, FABP3, FABP4, FABP5 |
BP | GO:0008152; metabolic process | GO:0009804; coumarin metabolic process | 5.331E-07 | 1.612E-04 | CYP1A1, CYP2A13, CYP2A6 |
BP | GO:0050896; response to stimulus | GO:0009725; response to hormone | 6.087E-07 | 1.816E-04 | AKR1B1, AR, CA2, CA9, CYP1A2, ESRRA, FABP3, FLT3, PPARA, TLR2, TSHR |
BP | GO:0008152; metabolic process | GO:0006691; leukotriene metabolic process | 1.093E-06 | 2.868E-04 | ABCC1, ALOX15, ALOX5, TLR2 |
MF | GO:0003824; catalytic activity | GO:0008389; coumarin 7-hydroxylase activity | 6.304E-06 | 1.445E-03 | CYP2A13, CYP2A6 |
BP | GO:0050896; response to stimulus | GO:0009636; response to toxic substance | 7.017E-06 | 1.592E-03 | AHR, AKR1B1, CA3, CYP1A1, CYP1B1, TLR2, TP53, TRPA1 |
BP | GO:0009987; cellular process | GO:0071310; cellular response to organic substance | 7.391E-06 | 1.659E-03 | AKR1B1, ALOX15, AR, CYP1A1, CYP1B1, DAPK1, FABP4, FLT3, HIF1A, NOX4, PPARD, TP53, TSHR |
BP | GO:0050896; response to stimulus | GO:0010038; response to metal ion | 1.486E-05 | 3.208E-03 | ALOX15, CA2, CYP1A1, CYP1A2, FABP4, HIF1A, TP53 |
MF | GO:0060089; molecular transducer activity | GO:0003707; steroid hormone receptor activity | 1.501E-05 | 3.208E-03 | AR, ESRRA, PPARA, PPARD |
BP | GO:0009987; cellular process | GO:0032849; positive regulation of cellular pH reduction | 1.888E-05 | 3.916E-03 | CA2, CA7 |
BP | GO:0008152; metabolic process | GO:0009404; toxin metabolic process | 2.622E-05 | 5.237E-03 | CYP1A1, CYP1A2, CYP1B1 |
BP | GO:0009987; cellular process | GO:1902533; positive regulation of intracellular signal transduction | 2.647E-05 | 5.241E-03 | AKR1B1, ALOX15, AR, CYP1B1, FLT3, MIF, NOX4, PPARD, TLR2, TP53, XDH |
BP | GO:0008152; metabolic process | GO:0008210; estrogen metabolic process | 2.991E-05 | 5.763E-03 | CYP1B1, HSD17B1, HSD17B2 |
BP | GO:0008152; metabolic process | GO:0009299; mRNA transcription | 3.392E-05 | 6.480E-03 | HIF1A, PPARD, TP53 |
BP | GO:0008152; metabolic process | GO:0018894; dibenzo-p-dioxin metabolic process | 3.770E-05 | 6.899E-03 | CYP1A1, CYP1A2 |
MF | GO:0003824; catalytic activity | GO:0034875; caffeine oxidase activity | 3.770E-05 | 6.899E-03 | CYP1A2, CYP2C9 |
BP | GO:0050896; response to stimulus | GO:0042060; wound healing | 4.316E-05 | 7.640E-03 | ALOX15, PPARA, PPARD, TP53 |
BP | GO:0050896; response to stimulus | GO:0033273; response to vitamin | 5.526E-05 | 9.705E-03 | CYP1A1, PPARD, TP53, TYR |
MF | GO:0003824; catalytic activity | GO:0004089; carbonate dehydratase activity | 1.230E-23 | 2.678E-19 | CA1, CA12, CA14, CA2, CA3, CA4, CA5A, CA6, CA7, CA9 |
BP | GO:0051179; localization | GO:0015701; bicarbonate transport | 9.636E-18 | 5.245E-14 | CA1, CA12, CA14, CA2, CA3, CA4, CA5A, CA6, CA7, CA9 |
BP | GO:0008152; metabolic process | GO:0006730; one-carbon metabolic process | 1.786E-16 | 5.556E-13 | CA1, CA12, CA2, CA3, CA4, CA5A, CA6, CA7, CA9 |
BP | GO:0008152; metabolic process | GO:0019373; epoxygenase P450 pathway | 4.891E-14 | 9.682E-11 | CYP1A1, CYP1A2, CYP1B1, CYP2A13, CYP2A6, CYP2C19, CYP2C9 |
Pathway ID | Pathway Name | p-Value | Adjusted p-Value | Enriched Genes |
---|---|---|---|---|
hsa00910 | Nitrogen metabolism_Homo sapiens_hsa00910 | 5.606E-23 | 5.774E-21 | CA12; CA1; CA3; CA2; CA5A; CA4; CA7; CA6; CA9; CA14 |
hsa05204 | Chemical carcinogenesis_Homo sapiens_hsa05204 | 1.121E-09 | 5.774E-08 | CYP2C9; CYP2A6; CYP2A13; CYP1A2; CYP1A1; CYP1B1; CYP2C19 |
hsa00980 | Metabolism of xenobiotics by cytochrome P450_Homo sapiens_hsa00980 | 2.368E-08 | 6.098E-07 | CYP2C9; CYP2A6; CYP2A13; CYP1A2; CYP1A1; CYP1B1 |
hsa03320 | PPAR signaling pathway_Homo sapiens_hsa03320 | 1.680E-08 | 5.769E-07 | FABP2; FABP3; FABP4; FABP5; PPARA; PPARD |
hsa04913 | Ovarian steroidogenesis_Homo sapiens_hsa04913 | 1.396E-07 | 2.396E-06 | HSD17B1; ALOX5; HSD17B2; CYP1A1; CYP1B1 |
hsa00140 | Steroid hormone biosynthesis_Homo sapiens_hsa00140 | 2.974E-07 | 4.377E-06 | HSD17B1; CYP1A2; HSD17B2; CYP1A1; CYP1B1 |
hsa01100 | Metabolic pathways_Homo sapiens_hsa01100 | 5.998E-06 | 6.864E-05 | GAA; ALOX15; AKR1B1; CYP2C19; TYR; CYP2C9; CYP2A6; HSD17B1; ALOX5; HSD17B2; CYP1A2; CYP1A1; XDH |
hsa00591 | Linoleic acid metabolism_Homo sapiens_hsa00591 | 7.218E-07 | 9.293E-06 | CYP2C9; CYP1A2; ALOX15; CYP2C19 |
hsa00590 | Arachidonic acid metabolism_Homo sapiens_hsa00590 | 1.598E-05 | 1.646E-04 | CYP2C9; ALOX5; ALOX15; CYP2C19 |
hsa00830 | Retinol metabolism_Homo sapiens_hsa00830 | 1.929E-05 | 1.806E-04 | CYP2C9; CYP2A6; CYP1A2; CYP1A1 |
hsa00982 | Drug metabolism - cytochrome P450_Homo sapiens_hsa00982 | 2.445E-05 | 2.099E-04 | CYP2C9; CYP2A6; CYP1A2; CYP2C19 |
hsa05200 | Pathways in cancer_Homo sapiens_hsa05200 | 4.004E-04 | 2.750E-03 | AR; FLT3; DAPK1; HIF1A; TP53; PPARD |
hsa04726 | Serotonergic synapse_Homo sapiens_hsa04726 | 1.626E-04 | 1.196E-03 | CYP2C9; ALOX5; ALOX15; CYP2C19 |
hsa00380 | Tryptophan metabolism_Homo sapiens_hsa00380 | 1.281E-04 | 1.015E-03 | CYP1A2; CYP1A1; CYP1B1 |
hsa05230 | Central carbon metabolism in cancer_Homo sapiens_hsa05230 | 5.929E-04 | 3.817E-03 | FLT3; TP53; HIF1A |
hsa00232 | Caffeine metabolism_Homo sapiens_hsa00232 | 1.377E-07 | 2.396E-06 | CYP2A6; CYP1A2; XDH |
hsa04923 | Regulation of lipolysis in adipocytes_Homo sapiens_hsa04923 | 8.323E-03 | 3.696E-02 | FABP4; TSHR |
hsa05221 | Acute myeloid leukemia_Homo sapiens_hsa05221 | 8.613E-03 | 3.696E-02 | FLT3; PPARD |
hsa05219 | Bladder cancer_Homo sapiens_hsa05219 | 4.537E-03 | 2.336E-02 | DAPK1; TP53 |
hsa00350 | Tyrosine metabolism_Homo sapiens_hsa00350 | 3.323E-03 | 1.801E-02 | MIF; TYR |
hsa00983 | Drug metabolism - other enzymes_Homo sapiens_hsa00983 | 5.682E-03 | 2.660E-02 | CYP2A6; XDH |
hsa02010 | ABC transporters_Homo sapiens_hsa02010 | 5.209E-03 | 2.555E-02 | ABCC1; ABCG2 |
hsa00052 | Galactose metabolism_Homo sapiens_hsa00052 | 2.448E-03 | 1.401E-02 | GAA; AKR1B1 |
hsa04964 | Proximal tubule bicarbonate reclamation_Homo sapiens_hsa04964 | 1.440E-03 | 8.722E-03 | CA2; CA4 |
ICD10 Disease Category | Disease Name | ICD10 Code | Linked Targets |
---|---|---|---|
C00-D49: Neoplasms | Prostate cancer | C61 | AR; AR; FLT3; TLR2 |
L00-L99: Diseases of the skin and subcutaneous tissue | Pruritus | L29 | ALOX5 |
N00-N99: Diseases of the genitourinary system | Prostate hyperplasia | N40 | AR |
L00-L99: Diseases of the skin and subcutaneous tissue | Psoriasis | L40 | ALOX5; FLT3 |
L00-L99: Diseases of the skin and subcutaneous tissue | Acne vulgaris | L70.0 | AR; AR; ESRRA |
E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic neuropathy | E11.40 | AKR1B1 |
C00-D49: Neoplasms | Myeloid leukemia | C92 | FLT3 |
C00-D49: Neoplasms | Myelodysplastic syndrome | D46 | TLR2 |
C00-D49: Neoplasms | Myelofibrosis | C94.4, D47.4 | FLT3 |
I00-I99: Diseases of the circulatory system | Pulmonary arterial hypertension | I27.0, I27.2 | HIF1A |
R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Cachexia | R64 | AR; ESRRA |
C00-D49: Neoplasms | Cancer | C00-C96 | AR; TP53; HIF1A; CA1; FLT3; FLT3; CA9; TLR2 |
S00-T88: Injury, poisoning and certain other consequences of external causes | Allergy | T78.4 | ALOX5 |
Z00-Z99: Factors influencing health status and contact with health services | Contraception | Z30 | AR |
M00-M99: Diseases of the musculoskeletal system and connective tissue | Osteoarthritis | M15-M19, M47 | ALOX5 |
E00-E89: Endocrine, nutritional and metabolic diseases | Non-insulin dependent diabetes | E11.9 | ESRRA |
K00-K95: Diseases of the digestive system | Non-alcoholic fatty liver disease | K76.0 | PPARD |
D50-D89: Diseases of the blood and blood-forming organs and certain disorders involving the immune mechanism | Refractory autoimmune diseases | D84.9, M35.9 | MIF |
S00-T88: Injury, poisoning and certain other consequences of external causes | Radiation sickness | T66 | TLR2 |
H00-H59: Diseases of the eye and adnexa | Choroidal neovascularisation | H35 | ESRRA |
C00-D49: Neoplasms | Colorectal cancer | C18-C21 | TP53; FLT3 |
C00-D49: Neoplasms | Colon cancer | C50 | FLT3 |
G00-G99: Diseases of the nervous system G00-G99 | Neurodegenerative disease | G30-G32 | MAPT |
E00-E89: Endocrine, nutritional and metabolic diseases | Metabolic disorders | E70-E89 | PPARD |
J00-J99: Diseases of the respiratory system | Respiratory disease | J00-J99 | ALOX5 |
I00-I99: Diseases of the circulatory system | Renal artery disease | I70.1 | TP53 |
C00-D49: Neoplasms | Renal cancer | C64 | CA9 |
NA: NA | Hematopoietic stem cell transplantation | NA | FLT3 |
E00-E89: Endocrine, nutritional and metabolic diseases | Autoimmune diabetes | E08-E13 | MIF; TLR2 |
C00-D49: Neoplasms | Oral cavity cancer | C00-C08 | TP53 |
H60-H95: Diseases of the ear and mastoid process | Hearing disorder | H90.5 | TP53 |
H00-H59: Diseases of the eye and adnexa | Open-angle glaucoma | H40-H42 | CA2; CA4 |
H00-H59: Diseases of the eye and adnexa | Ocular hypertension | H40.0 | CA4; CA4 |
C00-D49: Neoplasms | Pancreatic cancer | C25 | FLT3; TLR2 |
G00-G99: Diseases of the nervous system G00-G99 | Pain | G64, G90.0, R52, G89 | AR; TRPA1 |
C00-D49: Neoplasms | Leukemia | C90-C95 | FLT3 |
E00-E89: Endocrine, nutritional and metabolic diseases | Hyperuricaemia in gout | E79.0, M10 | XDH |
E00-E89: Endocrine, nutritional and metabolic diseases | Hypogonadism | E23.0, E28.3, E29.1 | AR |
M00-M99: Diseases of the musculoskeletal system and connective tissue | Muscle atrophy | M62.5 | AR |
M00-M99: Diseases of the musculoskeletal system and connective tissue | Osteoporosis | M80-M81, Z79.890 | AR |
M00-M99: Diseases of the musculoskeletal system and connective tissue | Osteoporosis in post-menopausal women | M80-M81 | AR |
C00-D49: Neoplasms | Metastatic castration-resistant prostate cancer | C61 | AR |
E00-E89: Endocrine, nutritional and metabolic diseases | Pompe's disease | E74.02 | GAA |
C00-D49: Neoplasms | Metastatic prostate cancer | C61 | AR |
J00-J99: Diseases of the respiratory system | Throat irritation | J39.2 | TRPA1 |
I00-I99: Diseases of the circulatory system | Thrombosis | I80-I82 | ALOX5 |
C00-D49: Neoplasms | Female androgenresponsive recurrent mammary cancer | C50 | AR |
C00-D49: Neoplasms | Acute lymphoblastic leukemia | C91.0 | FLT3 |
A00-B99: Certain infectious and parasitic diseases | Human immunodeficiency virus infection | B20-B26 | FLT3 |
E00-E89: Endocrine, nutritional and metabolic diseases | Male hormonal deficiencies | E20-E35 | AR |
A00-B99: Certain infectious and parasitic diseases | Fungal infections | B35-B49 | ALOX5 |
E00-E89: Endocrine, nutritional and metabolic diseases | Hyperuricemia | E79.0 | XDH |
C00-D49: Neoplasms | Acute myeloid leukemia | C92.0 | TP53; TP53; FLT3; FLT3 |
C00-D49: Neoplasms | Melanoma | C43 | TYR; TLR2 |
L00-L99: Diseases of the skin and subcutaneous tissue | Melasma | L81.1 | TYR |
H00-H59: Diseases of the eye and adnexa | Chronic glaucoma | H40-H42 | CA1 |
E00-E89: Endocrine, nutritional and metabolic diseases | Testosterone deficiency | E29.1 | AR |
C00-D49: Neoplasms | Thyroid cancer | C73 | TSHR |
E00-E89: Endocrine, nutritional and metabolic diseases | Obesity | E66 | PPARD; PPARD |
C00-D49: Neoplasms | Head and neck cancer | C07-C14, C32-C33 | TP53; AKR1B1 |
I00-I99: Diseases of the circulatory system | Heart failure | I50 | AR; XDH |
C00-D49: Neoplasms | Late-stage solid tumors | C00-C75, C7A, C7B, D10-D36, D3A | TP53 |
L00-L99: Diseases of the skin and subcutaneous tissue | Dermatological disease | L00-L99 | AR; ESRRA |
E00-E89: Endocrine, nutritional and metabolic diseases | Diabetes | E23.2, N25.1 | AKR1B1 |
G00-G99: Diseases of the nervous system G00-G99 | Central nervous system disease | G00-G99 | PPARD; MAPT |
C00-D49: Neoplasms | Advanced prostate cancer | C61 | AR |
A00-B99: Certain infectious and parasitic diseases | Lymphatic filariasis | B74 | ALOX5 |
C00-D49: Neoplasms | Lymphoma | C81-C86 | HIF1A; CA9 |
C00-D49: Neoplasms | Breast cancer | C50 | AR; FLT3; FLT3; CA9 |
C00-D49: Neoplasms | Clear cell renal cell carcinoma | C64 | CA9 |
C00-D49: Neoplasms | CLL | NA | FLT3 |
M00-M99: Diseases of the musculoskeletal system and connective tissue | Gout | M10 | ABCC1; ABCC1; AKR1B1; XDH |
H00-H59: Diseases of the eye and adnexa | Glaucoma | H40-H42 | CA1; CA1; AKR1B1 |
NA: NA | GIST | NA | FLT3 |
C00-D49: Neoplasms | Gliosarcoma | NA | FLT3 |
C00-D49: Neoplasms | Glioblastoma | NA | FLT3 |
K00-K95: Diseases of the digestive system | Alcoholic hepatitis | K70.1 | AR |
C00-D49: Neoplasms | Inflammatory disease | C11, C44, K75.9, M00-M25 | ALOX5; MIF |
E00-E89: Endocrine, nutritional and metabolic diseases | Inflammation | E08-E13, E10.2, E11, E11.2, E13.2, I73.9, I80-I82, N00-N29, G89 | ALOX5 |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Insomnia | F51.0, G47.0 | CA2 |
I00-I99: Diseases of the circulatory system | Edema associated with congestive heart failure | I50, R60.9 | CA2 |
NA: NA | Edema | NA | CA2 |
G00-G99: Diseases of the nervous system G00-G99 | Encephalopathy | G93.4 | XDH |
J00-J99: Diseases of the respiratory system | Chronic obstructive pulmonary disease | J40-J44, J47 | ALOX5 |
K00-K95: Diseases of the digestive system | Gastrointestinal disease | K00-K93 | ESRRA |
C00-D49: Neoplasms | AML | NA | FLT3 |
G00-G99: Diseases of the nervous system G00-G99 | Alzheimer disease | G30 | MAPT |
L00-L99: Diseases of the skin and subcutaneous tissue | Alopecia | L65.9 | AR |
J00-J99: Diseases of the respiratory system | Allergic rhinitis | J00, J30, J31.0, T78.4 | ESRRA |
NA: NA | Male hypogonadism | NA | AR |
E00-E89: Endocrine, nutritional and metabolic diseases | Cystic fibrosis | E84 | AR |
E00-E89: Endocrine, nutritional and metabolic diseases | Hyperlipidaemia | E78 | PPARD |
NA: NA | Anaplastic mixed oligoastrocytoma | NA | FLT3 |
C00-D49: Neoplasms | Bladder cancer | C67 | AR |
L00-L99: Diseases of the skin and subcutaneous tissue | Dermatitis | L20-L30 | ALOX5; ESRRA |
J00-J99: Diseases of the respiratory system | Airway inflammation | J00-J99 | FLT3 |
C00-D49: Neoplasms | Castration-resistant prostate cancer | C61 | AR |
I00-I99: Diseases of the circulatory system | Cardiovascular disorder | I00-I99 | AR |
E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic complication | E08-E13 | AKR1B1 |
E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic cataract | E10.36, E11.36 | AKR1B1 |
NA: NA | HIV infections | NA | AHR |
I00-I99: Diseases of the circulatory system | High blood pressure | I10-I16 | CA2 |
C00-D49: Neoplasms | Hormone refractory prostate cancer | C61 | AR |
M00-M99: Diseases of the musculoskeletal system and connective tissue | Arthritis | M00-M25 | ALOX5; ABCC1; ESRRA |
J00-J99: Diseases of the respiratory system | Asthma | J45 | ALOX5; ALOX5; ESRRA |
I00-I99: Diseases of the circulatory system | Atherosclerosis | I70 | ALOX5; PPARD |
M00-M99: Diseases of the musculoskeletal system and connective tissue | Rheumatoid arthritis | M05-M06 | ALOX5; TYR; AKR1B1; ESRRA |
J00-J99: Diseases of the respiratory system | Rhinitis | J00, J30, J31.0 | ALOX5 |
W85-W99: Exposure to electric current, radiation and extreme ambient air temperature and pressure | Diagnostic test to differentiate primary and secondary hypothyroidism | W88 | TSHR |
C00-D49: Neoplasms | Multiple myeloma | C90 | AHR |
C00-D49: Neoplasms | Hematological malignancies | C81-C86 | TP53 |
L00-L99: Diseases of the skin and subcutaneous tissue | Atopic dermatitis | L00-L99 | ALOX5 |
A00-B99: Certain infectious and parasitic diseases | Bacterial infections | A00-B99 | CYP2C9 |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Schizophrenia | F20 | ESRRA |
E00-E89: Endocrine, nutritional and metabolic diseases | Hormone deficiency | E00-E90 | AR |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Cognitive disorders | F01-F07, F04, F05, R41.3 | MAPT |
K00-K95: Diseases of the digestive system | Duodenal ulcers | K25-K27 | CA2; CA1 |
NA: NA | Dyslipidemia | NA | PPARD |
E00-E89: Endocrine, nutritional and metabolic diseases | Dyslipidaemias | E78 | PPARD; PPARD |
E00-E89: Endocrine, nutritional and metabolic diseases | Endocrine disease | E00-E35 | AR |
C00-D49: Neoplasms | Solid tumours | C00-D48 | TP53; HIF1A; FLT3; CA9; TLR2 |
L00-L99: Diseases of the skin and subcutaneous tissue | Vitiligo | L80 | TYR |
E00-E89: Endocrine, nutritional and metabolic diseases | Type 2 diabetes | E11 | PPARD |
E00-E89: Endocrine, nutritional and metabolic diseases | Type 1 diabetes | E10 | PPARD |
C00-D49: Neoplasms | Thyroid cancer diagnosis | C73 | TSHR |
S00-T88: Injury, poisoning and certain other consequences of external causes | Toxicity | T36-T50, T51-T65 | TP53 |